PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
By A. Gros, P. Robbins, X. Yao, Yong F Li, S. Turcotte, E. Tran, J. Wunderlich, A. Mixon, S. Farid, M. Dudley and 6 more. 2014
994 citations recorded by the source corpus.
Subfields: Immunology, Oncology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- E. Wherry
- A. Schietinger
- P. Greenberg
- Rafi Ahmed
- Kristen E. Pauken
- Ton N. Schumacher
- D. Thommen
- Laura M. McLane
In Oncology
- A. Schietinger
- P. Greenberg
- Ton N. Schumacher
- E. Wherry
- Kristen E. Pauken
- Rafi Ahmed
- D. Thommen
- Padmanee Sharma
Citations in the corpus
- Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, result): “In support of these estimates, recent studies have demonstrated that neoantigens generated by somatic mutation are recognized by T cells in both mouse and human cancers (Linnemann et al., 2015; Gros et al., 2014; Tran et al., 2014; Gubin et al., 2014).”
- T Cell Dysfunction in Cancer (2018, methodology): “This approach was successfully used to demonstrate the superior tumor recognition capacity of PD-1+ compared with PD-1 T cells in tumors and peripheral blood of melanoma patients (Gros et al., 2014, 2016).”
- Overcoming T cell exhaustion in infection and cancer (2015, background): “In addition to PD-L1, PD-1 expression in the tumor may also be an important predictor of immune involvement since PD-1+ cells in the tumor indicate immune (likely lymphoid) infiltration while PD-L1 expression often reflects IFNγ production and potential tumor recognition by immune cells [16, 81].”
- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. (2019, background): “Indeed, IL-2 was the first cytokine used for cancer treatment to augment T cell function (38), and it remains a focal point for cancer immunotherapy.”
- Neoantigens: promising targets for cancer therapy (2023, background): “A reservoir of stem-like neoantigen-reactive TILs, such as CD8 cells expressing activation or exhaustion markers (PD-1, TIM-3, and LAG-3), expand prolifically and supply differentiated subsets promotes T cell persistence and long-term tumor control, thereby strengthening the anti-tumor response.(518”